Biological DMARDs can also block T-cell-derived factors: as noted previously, blockade of Th17-derived IL-17A may ameliorate CVD in psoriasis, although further studies are needed (18, 19, 21, 97). The gene discussed is IL17A; the disease is psoriasis.